Physician profile
Angela A Carollo
NPI 1306805585
$8,542.63
in general payments reported to CMS, 2019-2025
36 companies · $1,945 in 2025
The $1,945 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,533 · 2020: $826 · 2021: $630 · 2022: $569 · 2023: $1,296 · 2024: $1,744 · 2025: $1,945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,883 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,882.81 |
| Education | $101.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,445.30 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $643.54 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $622.80 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $602.80 | 2019-2025 | Tremfya, Stelara |
| Celgene Corporation | $562.33 | 2022-2024 | Zeposia |
| Allergan, INC. | $271.39 | 2019-2020 | |
| Boston Scientific Corporation | $221.27 | 2022-2025 | General - Hemostasis |
| Phathom Pharmaceuticals, INC. | $215.37 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $214.15 | 2019-2025 | Rebyota |
| Merck Sharp & Dohme LLC | $174.38 | 2019-2024 | Dificid, Zerbaxa, Recarbrio |
| Intercept Pharmaceuticals, INC. | $159.61 | 2020-2024 | Ocaliva |
| Aimmune Therapeutics, INC. | $152.62 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $146.59 | 2022-2025 | Dupixent |
| Braintree Laboratories, INC. | $144.02 | 2019-2025 | Suflave, Sutab |
| Qol Medical, LLC | $136.26 | 2020-2025 | Sucraid |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $135.41 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $109.30 | 2022-2023 | |
| Madrigal Pharmaceuticals | $79.88 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $60.62 | 2020-2024 | Linzess |
| Daiichi Sankyo INC. | $46.97 | 2019-2023 | Injectafer |
| Lilly USA, LLC | $42.66 | 2024 | Omvoh |
| Redhill Biopharma INC. | $39.01 | 2020-2021 | |
| Novo Nordisk INC | $37.00 | 2025 | Wegovy |
| Enterra Medical, INC. | $34.44 | 2024 | |
| Vivus LLC | $33.97 | 2025 | Pancreaze |
| Shire North American Group INC | $33.18 | 2019 | |
| Celltrion USA INC. | $28.18 | 2025 | Vegzelma |
| Organon LLC | $25.55 | 2021-2024 | |
| Genzyme Corporation | $22.86 | 2025 | |
| Shionogi INC | $21.49 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $21.30 | 2025 | Iqirvo |
| Ethicon US, LLC | $19.24 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $14.62 | 2019 | |
| Endo Pharmaceuticals INC. | $13.44 | 2019 | |
| Ucb, INC. | $11.08 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$9,291.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Carollo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.